Table 1.
Clinical characteristics of patient cohort.
| No. Patients | 27 |
|---|---|
| Median patient age, years (range) | 47 (20-68) |
| Lesion type mass (mass vs. NME) | |
| Mass | 24 |
| Mass + NME | 3 |
| Histologic type | |
| NST | 24 |
| Metaplastic carcinoma | 2 |
| Mixed IDC/ILC | 1 |
| MBR score | |
| 1 | 1 |
| 2 | 11 |
| 3 | 15 |
| ER status | |
| Positive | 15 |
| Negative | 12 |
| PR status | |
| Positive | 13 |
| Negative | 14 |
| HER2 status | |
| Positive | 3 |
| Negative | 23 |
| Not analyzed | 1 |
| pCR status | |
| pCR | 10 |
| non-pCR | 17 |
| Median time from therapy start to MRI scan, days (range) | |
| Early-treatment | 19 (15-26) |
| Mid-treatment | 81 (48-94) |
| Post-treatment | 153 (127-190) |
NME, non-mass enhancement; NST, invasive breast cancer of no special type; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; MBR, Modified Bloom-Richardson; ER, estrogen receptor; PR, progesteron receptor; HER2, Human Epidermal Growth Factor Receptor 2; pCR, pathological complete response.